Latest Breaking News On - Anand jeyasekharan - Page 3 : comparemela.com

Monopar Announces New Drug Candidate, MNPR-202, and

Development of novel Camsirubicin analog expands Monopar’s therapeutic pipeline.

United statesUnited kingdomNational university of singaporeSingapore generalChandler robinsonAnand jeyasekharanKimr tsuchimotoAndrew mazarMonopar therapeutics incCancer institute of singaporeResearch centres of excellenceExchange commissionCancer science institute of singaporeNational research foundationTherapeutics incMinistry of education

Monopar Announces New Drug Can - GuruFocus com

GuruFocus Article or News written by Marketwired and the topic is about:

United statesUnited kingdomNational university of singaporeSingapore generalChandler robinsonMonopartx linkedinAnand jeyasekharanKimr tsuchimotoAndrew mazarMonopar therapeutics incCancer institute of singaporeResearch centres of excellenceExchange commissionCancer science institute of singaporeNational research foundationTherapeutics inc

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNational university of singaporeSingapore generalChandler robinsonAnand jeyasekharanKimr tsuchimotoAndrew mazarMonopar therapeutics incCancer institute of singaporeResearch centres of excellenceExchange commissionCancer science institute of singaporeNational research foundationTherapeutics incMinistry of education

Singapore discovers way to predict chemotherapy resistance

A significant number of patients are resistant to such treatments and relapse soon afterwards

National university of singaporeSingapore generalAnand jeyasekharanCancer science institute of singaporeCancer science instituteNational universityAssociate professor david tanAssoc prof tanAsst profதேசிய பல்கலைக்கழகம் ஆஃப் சிங்கப்பூர்சிங்கப்பூர் ஜநரல்ஆனந்த் ஜெயசேகரன்புற்றுநோய் அறிவியல் நிறுவனம் ஆஃப் சிங்கப்பூர்புற்றுநோய் அறிவியல் நிறுவனம்தேசிய பல்கலைக்கழகம்இணை ப்ரொஃபெஸர் டேவிட் பழுப்பு

New biomarker could be used to determine resistance of ovarian cancer to platinum chemotherapy

Epithelial ovarian cancer (EOC) is the most common lethal gynaecological cancer. Ovarian cancer is usually treated with platinum-based chemotherapy; however, a significant number of patients are resistant to such treatments and relapse soon afterwards.

National university of singaporeSingapore generalMichal hoppeAnand jeyasekharanEmily hendersonCancer science institute of singaporeCancer science instituteNational universityAssociate professor david tanAssoc prof tanStudy first authorResearch fellowAsst prof jeyasekharanAssoc profAsst profOvarian cancer